Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue$170.53M$170.53M−0.8% vs Q1 2024 Net Income$25.29M$25.29M−41.4% vs Q1 2024 EPS Diluted$0.51$0.51−37.0% vs Q1 2024 Gross Profit$85,251,000−5.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$35,077,000−36.6% Free Cash Flowderived$24,380,000−47.6% Margins · derivedGross margin50.0%−2.4 pt vs Q1 2024
Operating margin21.9%−6.1 pt vs Q1 2024
Net margin14.8%−10.3 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end